Table 3.
Occurrence and hazard ratios of squamous cell cancer in 12 558 TNF inhibitor treated compared with 46 409 biologics-naive Swedish RA patients, and of basal cell cancer in 8827 TNF inhibitor treated compared with 43 675 biologics-naive Swedish RA patients
| Cancer type | No of events (person years of follow-up; No of events/100 000 person years) | Hazard ratio | |||
|---|---|---|---|---|---|
| TNF inhibitor treated | Biologics-naive | Adjusted for age and sex | Multivariate adjusted* | ||
| Squamous cell cancer | 191 (74 541; 256) | 847 (238 902; 354) | 1.43 (1.22 to 1.69) | 1.30 (1.10 to 1.55) | |
| Invasive | 67 (75 282; 89) | 342 (241 427; 142) | 1.39 (1.05 to 1.83) | 1.30 (0.98 to 1.73) | |
| In situ | 141 (74 759; 189) | 618 (239 984; 258) | 1.42 (1.17 to 1.72) | 1.28 (1.04 to 1.56) | |
| Basal cell cancer | 236 (37 080;636) | 1,587 (203 215; 781) | 1.21 (1.06 to 1.41) | 1.14 (0.98 to 1.33) | |
RA=rheumatoid arthritis; TNF=tumour necrosis factor.
*Adjusted for age, sex, birth year, country of birth, county of residency, educational level, and comorbidities until start of follow-up (hospital admissions/outpatient visits for chronic obstructive pulmonary disease, ischaemic heart disease, diabetes mellitus, knee/hip joint replacement surgery, psoriatic disease. and any other diagnosis of benign skin disease except actinic keratosis; patients with diagnosis of solid organ transplantation and/or invasive malignancy before or during follow-up were considered not at risk.